SCREENING PROGRAM Sample Clauses
SCREENING PROGRAM. (a) During the term of the Screening Program, NeoGenesis will utilize its proprietary technology and methods, including without limitation the ALIS method, to screen the NeoMorph Screening Library for activity with respect to each Target for purposes of identifying Active Compounds for further evaluation and development. Screening will be performed pursuant to the protocol for the Screening Program, as set forth in paragraphs 1-2 of ATTACHMENT A. With respect to each accepted Target provided by Schering under Section 2.1, NeoGenesis shall *= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. complete the screening of the NeoMorph Screening Library within [*] following the date that the Target is delivered to NeoGenesis. The results of such screening shall be provided to Schering through the Steering Committee in the form of a Preliminary Target Report (as defined in ATTACHMENT A). NeoGenesis shall provide Schering with samples of all Preliminary Compounds selected by the Steering Committee for further evaluation by Schering pursuant to paragraph 3 of ATTACHMENT A. Schering will evaluate such Preliminary Compounds in Target-based functional assays and/or secondary assays to identify Active Compounds, and will report the results of such evaluations to the Steering Committee, and NeoGenesis will promptly thereafter provide Schering with all available structural information for each Active Compound so identified. NeoGenesis will, at the direction of the Steering Committee, conduct initial optimization activities, as described in paragraph 4, of ATTACHMENT A, to identify Improved Active Compounds. It is acknowledged that all compounds generated from such initial optimization activities and having activity against the relevant Target shall be deemed to be Improved Active Compounds; provided that such optimization activities and all Improved Active Compounds arising therefrom shall not be deemed to be optimization of Lead Compounds for purposes of Section 2.1(e) or for determining Schering's financial obligations under Sections 4.3 and 4.4.
(b) NeoGenesis will, at the direction of the Steering Committee, conduct a full program of medicinal chemistry optimization activities, based upon those Selected Compounds identified as Lead Compounds that are suitable for optimization. Such optimization activities shall include the design and preparation of NeoMorph Focused Libraries based upon such Lead Compounds, and the sc...
SCREENING PROGRAM. 13 3.1 Screening Program. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 3.1.1 Screening by Aurora. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 3.1.2
SCREENING PROGRAM. During the Screening Term, PPI will employ exclusively assays A-D as described below to screen for A(beta) peptide polymerization inhibition activity for 50,000 compounds selected and supplied by BI. *** Depending on activity levels seen in Assay A, PPI may require additional material for Assays B-D and subsequent in vivo assays. PPI will deliver to BI SAR data on existing PPI Compounds within 6 weeks of the Effective Date. BI will deliver to PPI at least 13,000, 25,000, 37,500, and 50,000 compounds within 2.0, 5.0, 12.0, and 16.0 months respectively, of the Effective Date and PPI anticipates, barring any unforeseen technical issues, screening 25,000 compounds in its Nucleation Assay within 12 months and 50,000 compounds in its Nucleation Assay within 24 months of the Effective Date. Compounds jointly designated will be further screened in secondary assays described below. Assay Functional Measurement Manpower ----- ---------------------- -------- A. Nucleation Assay *** *** FTE B. Extension Assay *** *** FTE C. Neurotoxicity *** *** FTE D. Specificity *** *** FTE PPI will make available *** FTE's to the Screening Program immediately following the Effective Date. These FTE's will either be new hires or redeployments of existing personnel. PPI anticipates that it will be evaluating BI compounds in assays A-D within 6 weeks of first receiving compounds from BI. All Applicable data will be supplied to BI in PC compatible form (e.g. ASCI II or Excel files). All BI compounds will be handled or disposed of in accordance with BI's written instructions.
A. Nucleation Assay: A rapid high-throughput primary screen The nucleation assay *** Approximately 13 lines omitted ***
B. Extension Assay: *** The extension assay *** Approximately 6 lines omitted ***
C. Neurotoxicity Assay: in vitro Cellular Efficacy *** Approximately 10 lines omitted ***
D. Amyloid Specificity Assays *** Approximately 9 lines omitted ***
SCREENING PROGRAM. NeoGenesis will apply use its ALIS method to screen the NeoMorph Library for activity with respect to each Target for purposes of identifying potentially useful chemical compounds for further evaluation and development. Screening will be performed pursuant to the screening protocol for the Program set forth in ATTACHMENT A. NeoGenesis shall commence the Program following the date the Targets are delivered to NeoGenesis and shall complete the Program within [*] following the date that the Targets are delivered to NeoGenesis, unless the parties agree in writing to extend the period for performance of the Program (the SCREENING PERIOD).
SCREENING PROGRAM. (a) NeoGenesis will apply its ALIS method to screen the NeoMorph Library for activity with respect to each Target for purposes of identifying potentially useful chemical compounds for further evaluation and development. Screening will be performed pursuant to the screening protocol for the Program set forth in ATTACHMENT A. With respect to each Target delivered by OGS, NeoGenesis shall initiate its screening obligations as more particularly set out in the Program within [*] following the date of receipt of such Target and complete such screening obligations within [*] following the date it commences its screening obligations with respect to such Target, unless the parties agree in writing to extend the period for performance and except as otherwise provided in Section 2.1(a)(ii) (such period, the SCREENING PERIOD).
(b) Notwithstanding any provision of this Agreement to the contrary, it is understood and agreed that while NeoGenesis will attempt to complete the Program within thirty six (36) months following the Effective Date, in the event and to the extent that NeoGenesis has not completed the Program with respect to any Target(s) disclosed by OGS within thirty three (33) months following the Program Commencement Date (or thereafter with respect to Targets that are excluded by NeoGenesis as contemplated by Section 2.1(a)) NeoGenesis will continue to perform the Program during the period following the expiration of thirty six (36) months following the Effective Date until NeoGenesis completes the Program for each Target submitted in accordance with Section 2.1(a) and NeoGenesis shall not ▇▇▇▇ OGS any additional fees with respect to the work required to complete the Program with respect to such Targets following the expiration of such thirty six (36) month period; PROVIDED, OGS has paid all fees required under Section 4.2 and PROVIDED FURTHER that NeoGenesis may ▇▇▇▇ OGS for any additional fees due NeoGenesis in respect of "additional" work as contemplated by ATTACHMENT A (Items 6-7).
SCREENING PROGRAM. During the Screening Term, PPI will employ exclusively assays A-D as described below to screen for A(beta) peptide polymerization inhibition activity for 50,000 compounds selected and supplied by BI. *** Depending on activity levels seen in Assay A, PPI may require additional material for Assays B-D and subsequent in vivo assays. PPI will deliver to BI SAR data on existing PPI Compounds within 6 weeks of the Effective Date. BI will deliver to PPI at least 13,000, 25,000, 37,500, and 50,000 compounds within 2.0, 5.0, 12.0, and 16.0 months respectively, of the Effective Date and PPI anticipates, barring any unforeseen technical issues, screening 25,000 compounds in its Nucleation Assay within 12 months and 50,000 compounds in its Nucleation Assay within 24 months of the Effective Date. Compounds jointly designated will be further screened in secondary assays described below. Assay Functional Measurement Manpower ----- ---------------------- -------- A. Nucleation Assay *** *** FTE
SCREENING PROGRAM. (a) NeoGenesis will use its ALIS method to screen the NeoMorph Library for activity with respect to each Screening Target for purposes of identifying potentially useful chemical compounds for further *=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. evaluation and development. Screening will be performed pursuant to the screening protocol for the Program set forth in ATTACHMENT A.
(b) It is understood and agreed that while NeoGenesis will use Commercially Reasonable efforts to complete the Screening Program for all three Screening Targets within [*] following the Effective Date (the SCREENING PERIOD) and complete the Hit Exploration Program for all [*] Screening Targets within [*] following the Effective Date, in the event and to the extent that NeoGenesis has not completed the Screening Program with respect to any Screening Target(s) within such [*] period or completed the Hit Exploration Program within such [*] period, NeoGenesis will continue to perform the applicable Program services during the period following the expiration of the applicable period until NeoGenesis completes the Program for each Screening Target submitted in accordance with Sections 2.1-2.2 at no additional cost.
SCREENING PROGRAM. The Program to be performed by NeoGenesis with respect to the Targets will screen compounds contained in the NeoGenesis NeoMorph Screening Library as updated from time to time by NeoGenesis (collectively, such compounds are the Compounds).
SCREENING PROGRAM. (a) NeoGenesis will apply its ALIS method to screen the NeoMorph Library for activity with respect to each Target for purposes of identifying potentially useful chemical compounds for further evaluation and development. Screening will be performed pursuant to the screening protocol for the Program set forth in Attachment A. With respect to each Target delivered by OGS, NeoGenesis shall initiate its screening obligations as more particularly set out in the Program within thirty (30) days following the date of receipt of such Target and complete such screening obligations within ninety (90) days following the date it commences its screening obligations with respect to such Target, unless the parties agree in writing to extend the period for performance and except as otherwise provided in Section 2.1(a)(ii) (such period, the Screening Period).
SCREENING PROGRAM